20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Taysha Gene Therapies Inc (TSHA) operates in the BIOTECHNOLOGY industry and is headquartered in Dallas, United States with about 99 employees. Its market capitalization is roughly $2 billion. In the fiscal year ended 2025-12-31, TSHA reported $10M in revenue and ($109M) in net income.
Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system.
Interactive charts & full statements → Open the TSHA valuation workbench →
| Income statement | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | $5M | $10M | $8M | $15M | $3M | $0M | $0M | — |
| Gross Profit | — | $10M | $8M | $15M | $0M | $0M | $0M | — |
| Gross Margin % | — | 100.0% | 100.0% | 100.0% | 0.6% | — | — | — |
| Operating Income (EBIT) | ($153M) | ($110M) | ($91M) | ($72M) | ($126M) | ($173M) | ($43M) | ($1M) |
| Operating Margin % | -2792.3% | -1130.7% | -1097.5% | -468.8% | -5037.1% | — | — | — |
| Net Income | ($150M) | ($109M) | ($89M) | ($112M) | ($166M) | ($175M) | ($43M) | ($1M) |
| Net Margin % | -2728.0% | -1115.3% | -1071.6% | -722.1% | -6635.3% | — | — | — |
| EBITDA | ($149M) | ($108M) | ($88M) | ($105M) | ($160M) | ($173M) | ($60M) | ($1M) |
| Earnings Per Share (EPS) | $-0.42 | $-0.34 | $-0.36 | $-0.96 | $-3.78 | $-4.64 | $-2.43 | $-0.03 |
| Shares Outstanding (M) | 369M | 320M | 250M | 116M | 44M | 38M | 18M | 37M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $5M | $0M | $2M | $2M | $2M | $2M |
| Gross Profit | — | $0M | $5M | $0M | $2M | $2M | $2M | $2M |
| Gross Margin % | — | — | 94.5% | — | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating Income (EBIT) | ($47M) | ($43M) | ($28M) | ($34M) | ($27M) | ($21M) | ($20M) | ($26M) |
| Operating Margin % | — | — | -516.0% | — | -1347.1% | -930.5% | -985.8% | -1448.4% |
| Net Income | ($47M) | ($42M) | ($28M) | ($33M) | ($27M) | ($22M) | ($19M) | ($26M) |
| Net Margin % | — | — | -507.8% | — | -1353.6% | -935.2% | -929.0% | -1427.5% |
| EBITDA | ($46M) | ($42M) | ($28M) | ($32M) | ($27M) | ($21M) | ($18M) | ($25M) |
| Earnings Per Share (EPS) | $-0.13 | $-0.12 | $-0.09 | $-0.09 | $-0.09 | $-0.08 | $-0.09 | $-0.10 |
| Shares Outstanding (M) | 369M | 367M | 320M | 353M | 298M | 269M | 205M | 268M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($132M) | ($93M) | ($81M) | ($73M) | ($88M) | ($117M) | ($31M) | $0M |
| Capital Expenditures (CapEx) | $3M | $1M | $0M | $7M | $25M | $22M | $9M | $0M |
| Free Cash Flow (FCF) | ($136M) | ($94M) | ($82M) | ($80M) | ($113M) | ($139M) | ($40M) | $0M |
| FCF Margin % | -2471.7% | -960.1% | -979.2% | -520.3% | -4526.7% | — | — | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly cash flow | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($40M) | ($41M) | ($27M) | ($24M) | ($20M) | ($22M) | ($18M) | ($22M) |
| Capital Expenditures (CapEx) | $0M | $3M | $0M | $0M | $0M | $0M | $0M | $0M |
| Free Cash Flow (FCF) | ($40M) | ($44M) | ($27M) | ($24M) | ($20M) | ($22M) | ($18M) | ($22M) |
| FCF Margin % | — | — | -491.7% | — | -1016.3% | -973.0% | -905.5% | -1210.8% |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $470M | $343M | $160M | $173M | $126M | $214M | $259M | $0M |
| Cash & Cash Equivalents | $455M | $320M | $139M | $144M | $88M | $149M | $251M | — |
| Total Liabilities | $83M | $96M | $89M | $98M | $125M | $119M | $8M | $0M |
| Total Debt (Short + Long-Term) | $49M | $50M | $46M | $42M | $39M | $37M | $0M | $0M |
| Total Shareholders' Equity | $387M | $247M | $72M | $75M | $1M | $95M | $251M | $0M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive TSHA viewer.
About TickerBase · Data methodology & sources · Privacy · Terms